EvlaBio raises €21.0M Seed round
7 July 2025· Zurich, Switzerland· health, biotech, b2b, deep_hardware
The funding will be used to complete preclinical development and progress towards IND-enabling studies for a first-in-class monoclonal antibody therapy designed to treat left ventricular hypertrophy (LVH) in patients with chronic kidney disease (CKD).
Investors
LeadKurma Partners
Also participating
High-Tech GründerfondsBoehringer Ingelheim Venture FundKHAN Technology Transfer Fund INRW.VentureAdBio Partners
About EvlaBio
Stage
Seed
Headquarters
Zurich, Switzerland
Founded
2022
Team Size
6–20
Sectors
healthbiotechb2bdeep_hardware